503B is Launched

Anticipating the 503B Model, and focused on safety and quality, CAPS® launches one of the first successful FDA-registered 503B outsourcing facilities.


In an effort to provide predictability and transparency in the process of sterile compounding, Congress enacts the Drug Quality and Security Act, dividing compounding into 503A (patient-specific) and 503B (large-scale).